JP2023501580A5 - - Google Patents
Info
- Publication number
- JP2023501580A5 JP2023501580A5 JP2022527730A JP2022527730A JP2023501580A5 JP 2023501580 A5 JP2023501580 A5 JP 2023501580A5 JP 2022527730 A JP2022527730 A JP 2022527730A JP 2022527730 A JP2022527730 A JP 2022527730A JP 2023501580 A5 JP2023501580 A5 JP 2023501580A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- population
- cell
- grna
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962934991P | 2019-11-13 | 2019-11-13 | |
| US62/934,991 | 2019-11-13 | ||
| PCT/IB2020/060723 WO2021095013A1 (en) | 2019-11-13 | 2020-11-13 | Manufacturing process for making t cells expressing chimeric antigen receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023501580A JP2023501580A (ja) | 2023-01-18 |
| JP2023501580A5 true JP2023501580A5 (https=) | 2023-11-02 |
Family
ID=73598909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022527730A Pending JP2023501580A (ja) | 2019-11-13 | 2020-11-13 | キメラ抗原受容体を発現するｔ細胞を作製するための製造プロセス |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210139850A1 (https=) |
| EP (1) | EP4058560A1 (https=) |
| JP (1) | JP2023501580A (https=) |
| KR (1) | KR20220097984A (https=) |
| CN (1) | CN114929862A (https=) |
| AR (1) | AR120469A1 (https=) |
| AU (1) | AU2020382219A1 (https=) |
| BR (1) | BR112022009152A2 (https=) |
| CA (1) | CA3158122A1 (https=) |
| CO (1) | CO2022006008A2 (https=) |
| IL (1) | IL292329A (https=) |
| MX (1) | MX2022005818A (https=) |
| TW (1) | TW202132333A (https=) |
| WO (1) | WO2021095013A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116322716A (zh) | 2020-09-23 | 2023-06-23 | 克里斯珀医疗股份公司 | Regnase-1和/或TGFBRII被破坏的基因工程化T细胞具有改善的功能性和持久性 |
| TW202328444A (zh) * | 2021-07-26 | 2023-07-16 | 瑞士商Ｃｒｉｓｐｒ治療公司 | 用於製造基因工程化ｃａｒ－ｔ細胞之方法 |
| WO2023084399A1 (en) * | 2021-11-09 | 2023-05-19 | Crispr Therapeutics Ag | Genetically engineered immune cells expressing masked chimeric antigen receptors specific to protein tyrosine kinase 7 |
| US20230303713A1 (en) * | 2022-03-23 | 2023-09-28 | Crispr Therapeutics Ag | Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof |
| WO2025196582A1 (en) * | 2024-03-18 | 2025-09-25 | Immuneel Therapeutics Private Limited | A method for preparing chimeric antigen receptor (car) expressing cells |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013266968B2 (en) * | 2012-05-25 | 2017-06-29 | Emmanuelle CHARPENTIER | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| CN113355357B (zh) * | 2012-12-12 | 2024-12-03 | 布罗德研究所有限公司 | 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化 |
| US8697359B1 (en) * | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| ES2836743T3 (es) * | 2014-06-02 | 2021-06-28 | Us Health | Receptores de antígeno quiméricos que seleccionan como diana CD-19 |
| GB201418965D0 (https=) * | 2014-10-24 | 2014-12-10 | Ospedale San Raffaele And Fond Telethon | |
| US20170335331A1 (en) * | 2014-10-31 | 2017-11-23 | The Trustees Of The University Of Pennsylvania | Altering Gene Expression in CART Cells and Uses Thereof |
| CN107250373A (zh) * | 2015-01-12 | 2017-10-13 | 麻省理工学院 | 通过微流体递送实现的基因编辑 |
| EP4628587A3 (en) * | 2016-04-15 | 2026-02-25 | Memorial Sloan Kettering Cancer Center | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
| US20190136230A1 (en) * | 2016-05-06 | 2019-05-09 | Juno Therapeutics, Inc. | Genetically engineered cells and methods of making the same |
| CN109790519A (zh) * | 2016-06-22 | 2019-05-21 | 塞尔丽思股份公司 | 细胞靶向的药物活性物质或标记物递送体系 |
| DE102016211884A1 (de) | 2016-06-30 | 2018-01-04 | Zf Friedrichshafen Ag | Getriebe für ein Kraftfahrzeug, sowie Antriebsstrang für ein Kraftfahrzeug |
| US20200087681A1 (en) * | 2016-12-21 | 2020-03-19 | Ucl Business Plc | Therapeutic cells |
| WO2018157072A1 (en) * | 2017-02-27 | 2018-08-30 | Life Technologies Corporation | Expansion of populations of t cells by the use of modified serum free media |
| MX2019013514A (es) * | 2017-05-12 | 2020-01-20 | Crispr Therapeutics Ag | Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia. |
| CN107392652A (zh) | 2017-06-30 | 2017-11-24 | 广州市中崎商业机器股份有限公司 | 基于收银纸背面进行针对性广告发布的系统及方法 |
| AU2018313167A1 (en) * | 2017-08-08 | 2020-02-27 | Sangamo Therapeutics, Inc. | Chimeric antigen receptor mediated cell targeting |
| CN108192927A (zh) * | 2017-12-29 | 2018-06-22 | 上海海洋大学 | 一种瓯江彩鲤的基因编辑与过表达操作方法 |
| BR112020016176A2 (pt) * | 2018-02-09 | 2022-02-22 | Immatics Us Inc | Métodos de transdução de uma célula t, célula t transduzida geneticamente, composição farmacêutica, métodos de preparação de uma população de células t e uso da célula t |
| MX2020012028A (es) | 2018-05-11 | 2021-03-29 | Crispr Therapeutics Ag | Metodos y composiciones para tratar el cancer. |
-
2020
- 2020-11-13 CN CN202080087663.5A patent/CN114929862A/zh active Pending
- 2020-11-13 WO PCT/IB2020/060723 patent/WO2021095013A1/en not_active Ceased
- 2020-11-13 CA CA3158122A patent/CA3158122A1/en active Pending
- 2020-11-13 EP EP20815928.5A patent/EP4058560A1/en active Pending
- 2020-11-13 BR BR112022009152A patent/BR112022009152A2/pt not_active Application Discontinuation
- 2020-11-13 US US17/098,212 patent/US20210139850A1/en active Pending
- 2020-11-13 MX MX2022005818A patent/MX2022005818A/es unknown
- 2020-11-13 JP JP2022527730A patent/JP2023501580A/ja active Pending
- 2020-11-13 TW TW109139764A patent/TW202132333A/zh unknown
- 2020-11-13 AU AU2020382219A patent/AU2020382219A1/en active Pending
- 2020-11-13 KR KR1020227019513A patent/KR20220097984A/ko not_active Withdrawn
- 2020-11-13 AR ARP200103160A patent/AR120469A1/es not_active Application Discontinuation
- 2020-11-13 IL IL292329A patent/IL292329A/en unknown
-
2022
- 2022-05-09 CO CONC2022/0006008A patent/CO2022006008A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023501617A5 (https=) | ||
| JP2023501580A5 (https=) | ||
| US20250002850A1 (en) | Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors | |
| AU2018202976B2 (en) | Polyclonal gamma delta t cells for immunotherapy | |
| JP7190096B2 (ja) | 遺伝子編集ｔ細胞及びその使用 | |
| CN115175695A (zh) | 制备表达嵌合抗原受体的细胞的方法 | |
| TW202030323A (zh) | 製備表現嵌合抗原受體的細胞之方法 | |
| BR112020007710A2 (pt) | métodos para produzir células que expressam receptor de antígeno quimérico | |
| TW201903145A (zh) | 將基因編輯用於產生通用型ｔ細胞受體重導向的ｔ細胞以進行輸入免疫治療的用途 | |
| JP2018512162A5 (https=) | ||
| CN105112370A (zh) | 一种体外刺激外周血γδT细胞高效增殖的方法及其应用 | |
| CN114929862A (zh) | 用于制备表达嵌合抗原受体的t细胞的生产方法 | |
| WO2024140778A1 (zh) | Nkg2d工程化细胞及其组合物 | |
| CN117616039A (zh) | 嵌合抗原受体及包含其的经修饰细胞 | |
| JP2025066794A (ja) | 遺伝子改変自己ｔ細胞を製造するためのプロセス | |
| JP2024525609A5 (https=) | ||
| TW202323521A (zh) | 製備表現嵌合抗原受體的細胞之方法 | |
| US20230054266A1 (en) | Method for purifying ucart cell and use thereof | |
| CN115835873A (zh) | 用于产生表达重组受体的供体分批细胞的方法 | |
| CN116622712A (zh) | 用于敲除t细胞中的trac和b2m的试剂和方法 | |
| CN109563484A (zh) | 用于细胞活化的方法和试剂盒 | |
| CN105950645A (zh) | Car-cd19抗原受体的人源化融合基因片段、其构建方法及应用 | |
| WO2024193714A1 (zh) | 细胞免疫疗法的组合物和方法 | |
| Guha et al. | Strategies for manufacturing cell therapy products aligned with patient needs | |
| WO2025040046A1 (zh) | 体内半衰期延长的工程化t细胞及其制备方法 |